SEC Form 4 · accession 0000899243-16-028737
CURIS INC · CRIS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.01 per share | Sep 7, 2016 | P | 10,208,333 | $2.40 | A | 27,328,464 | D |
Table II — derivative securities
Remarks
Aurigene Discovery Technologies Limited ("Aurigene") has acquired from the Issuer an additional 10,208,333 shares of Common Stock, par value $0.01 per share, of the Issuer at a purchase price of $2.40 per share. 1. This Form 4 is being filed jointly by (i) Aurigene Discovery Technologies Limited ("Aurigene"), which (after giving effect to the acquisition of an additional 10,208,333 shares as described above) directly holds 27,328,464 shares of Common Stock of the Issuer (the "Reported Securities"), (ii) Dr. Reddy's Laboratories Ltd. ("DRL"), as the parent company and 100% owner of Aurigene, and (iii) Dr. Reddy's Holdings Ltd. ("DRHL"), in the event that it could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL. 2. In the event that DRHL could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL, its proportional pecuniary interest in such Reported Securities would be approximately 24.262%, which would represent approximately 6,630,545 shares of Common Stock of the Issuer. 3. The filing of this Form 4 shall not be deemed an admission for the purposes of Section 16 or any other purpose that any reporting person is the beneficial owner of any Reported Securities, and DRHL expressly disclaims that it is the beneficial owner of any of the Reported Securities.